Novartis reported a core operating profit of $4.93 billion in fourth-quarter 2025, representing a 1 percent year-on-year increase and driving core operating margin up to 37.0 percent, a 0.1 percentage-point improvement. Adjusted EPS of $2.03 beat consensus by $0.04, reflecting disciplined cost management that offset a 15 percentage-point headwind from generic competition on key brands. Although net sales of $13.34 billion fell short of estimates, the company maintained a net margin of 26.5 percent and logged free cash flow above $6 billion for the full year, underpinning its ability to fund R&D and shareholder returns.

Trading at a single-digit PEG ratio below peer averages, Novartis offers a value opportunity supported by anticipated EPS growth of 8 percent in the current fiscal year. Management has accelerated its share repurchase program, authorizing up to $5 billion of buybacks over the next 12 months, and has already deployed $2 billion in the first quarter. This steady reduction in share count, combined with a debt-to-equity ratio of 0.50, positions the company to enhance per-share metrics while preserving financial flexibility.

Novartis expects seven pivotal clinical readouts in the coming months across oncology, immunology and cardiovascular indications. Highlights include Phase III data for a novel Bruton’s tyrosine kinase inhibitor targeting autoimmune diseases, an FDA submission for a next-generation heart failure therapy, and planned filings for two oncology candidates showing mid-teens percentage point improvements in progression-free survival. These milestones are critical to offset upcoming patent expiries on Entresto and Promacta, and to support management’s guidance for low-single-digit sales growth in fiscal 2026.